RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+33.89%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.72B
AUM Growth
+$2.72B
(-2.6%)
Cap. Flow
-$414M
Cap. Flow
% of AUM
-15.2%
Top 10 Holdings %
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Top Buys
| 1 |
SLN
Silence Therapeutics
SLN
|
$43.8M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$40.2M |
| 3 |
Keros Therapeutics
KROS
|
$36.6M |
| 4 |
Stoke Therapeutics
STOK
|
$33M |
| 5 |
Immunome
IMNM
|
$24.9M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$487M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$115M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$67.7M |
| 4 |
Krystal Biotech
KRYS
|
$40M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$26.4M |
Sector Composition
| 1 | Healthcare | 97.54% |
| 2 | Industrials | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Annexon
ANNX
$225M
| $39.5M | 1.45% |
5,503,190
| – | – |
|
27
Boston Scientific
BSX
$159B
| $38.4M | 1.41% |
560,926
-132,274
| -19% | -$9.06M |
|
28
Celldex Therapeutics
CLDX
$1.57B
| $37.6M | 1.38% |
896,454
-97,349
| -10% | -$4.09M |
|
|
29
Keros Therapeutics
KROS
$640M
| $36.6M | 1.34% |
+552,506
| New | +$36.6M |
|
|
CTLT
30
DELISTED
CATALENT, INC.
CTLT
| $35.7M | 1.31% |
632,464
-468,002
| -43% | -$26.4M |
|
31
Immunovant
IMVT
$2.91B
| $31.3M | 1.15% |
969,621
-7,451
| -0.8% | -$241K |
|
32
Replimune Group
REPL
$460M
| $30.5M | 1.12% |
3,729,983
-135,275
| -3% | -$1.11M |
|
33
Abbott
ABT
$230B
| $29.8M | 1.09% |
262,371
-3,129
| -1% | -$356K |
|
|
IGMS
34
DELISTED
IGM Biosciences
IGMS
| $29.6M | 1.09% |
3,072,478
+100,936
| +3% | +$974K |
|
35
Align Technology
ALGN
$9.59B
| $28.6M | 1.05% |
87,255
+37,173
| +74% | +$12.2M |
|
36
Cogent Biosciences
COGT
$1.83B
| $26.6M | 0.98% |
3,962,602
+1,048,580
| +36% | +$7.05M |
|
37
89bio
ETNB
$1.37B
| $26.4M | 0.97% |
2,264,566
+295,164
| +15% | +$3.44M |
|
38
Cigna
CI
$80.2B
| $23.8M | 0.87% |
+65,435
| New | +$23.8M |
|
39
Evolent Health
EVH
$1.11B
| $22.3M | 0.82% |
679,172
-156,365
| -19% | -$5.13M |
|
|
VERV
40
DELISTED
Verve Therapeutics
VERV
| $21.3M | 0.78% |
1,604,515
-114,154
| -7% | -$1.52M |
|
41
Entrada Therapeutics
TRDA
$202M
| $18.2M | 0.67% |
1,283,735
| – | – |
|
42
HCA Healthcare
HCA
$95.4B
| $17.5M | 0.64% |
52,487
-13,613
| -21% | -$4.54M |
|
43
Elevance Health
ELV
$72.4B
| $16.2M | 0.59% |
31,223
+8,144
| +35% | +$4.22M |
|
44
Ardelyx
ARDX
$1.57B
| $16M | 0.59% |
+2,194,560
| New | +$16M |
|
|
BOLD
45
Boundless Bio
BOLD
$25.7M
| $15.9M | 0.58% |
+1,114,034
| New | +$15.9M |
|
46
Stryker
SYK
$149B
| $15.5M | 0.57% |
43,246
-9,895
| -19% | -$3.54M |
|
|
GRTS
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $14.8M | 0.54% |
5,755,075
-117,530
| -2% | -$302K |
|
48
Prime Medicine
PRME
$595M
| $14.5M | 0.53% |
2,074,350
+750,000
| +57% | +$5.25M |
|
49
Icon
ICLR
$14B
| $12.4M | 0.46% |
+36,949
| New | +$12.4M |
|
50
Progyny
PGNY
$2.02B
| $12.2M | 0.45% |
+320,864
| New | +$12.2M |
|